ASH 2014 | Paediatric treatment regimens for acute lymphoblastic leukaemia in adolescents and young adults

Wendy Stock

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL) discusses the intergroup trial C10403, which showed that adolescent and young adult patients (16–39 years old) with acute lymphoblastic leukaemia had better overall and event-free survival with paediatric regimens compared to historical controls.

Share this video  
Similar topics